ppt 42107 Euro Deflation Undercuts Recovery Myth by Jason Galanis
Bristol Meyers Takes a Punch by Jason galanis
5
@ 2015. All Rights Reserved By Jason W Galanis. Bristol Meyers Takes a Punch Friday, Bristol Meyers took a punch in the nose over its disappointing can news about its new cancer drug Option. It was not as effective as had been expected in treating melanoma and lung cancer with low- level proteins. The company had high expectations for the drugs effect on cancer cells. The study showed that previously treated patients with advanced squamous non-small cell cancer had an overall survival rate of 42% after one year, compared to a 24% survival rate with Docetaxel. However, the results were not as good as had been expected. Many people chose to sell the stock on the news.
-
Upload
jason-w-galanis -
Category
Documents
-
view
1 -
download
0
description
Friday, Bristol Meyers took a punch in the nose over its disappointing can news about its new cancer drug Opdivo. It was not as effective as had been expected in treating melanoma and lung cancer with low-level proteins.
Transcript of Bristol Meyers Takes a Punch by Jason galanis
PowerPoint Presentation
@ 2015. All Rights Reserved By Jason W Galanis.Bristol Meyers Takes a PunchFriday, Bristol Meyers took a punch in the nose over its disappointing can news aboutits new cancer drug Option. It was not as effective as had been expected in treating melanoma and lung cancer with low-level proteins.
The company had high expectations for the drugs effect on cancer cells.
The study showed that previously treated patients with advanced squamous non-small cell cancer had an overall survival rate of 42% after one year, compared to a 24% survival rate with Docetaxel.
However, the results were not as good as had been expected. Many people chose to sell the stock on the news.
1@ 2015. All Rights Reserved By Jason W Galanis.
2@ 2015. All Rights Reserved By Jason W Galanis.Bristol Meyers Takes a PunchBristol Meyers stock dropped 6 percent on the news.
Many analysts believe that the company got unfair treatment because it has such a solid pipeline of products.
The company has many other successful drugs in the market.
The stock dropped $4.55 per share to $64.60. Bristol Meyers has traded as high as $60.86 this year.
Its low has been $45.30; so this bad news has not damaged the stock too badly. It is down from a recent high.3@ 2015. All Rights Reserved By Jason W Galanis.Bristol Meyers Takes a PunchRecently, there has been a major push from some of the top pharmaceutical/biotech companies to come up with a new drug that helps the immune system attack cancer cells inside that body.
Bristol Meyers had been in trials using both Option and another of their immunotherapy drugs together. This combination showed good results.
The two drugs together are very expensive and they do have side effects. However, given Bristol Meyers advances in immunotherapy not only for lung cancer and melanoma, but other cancers as well, the price drop is likely only temporary.
For investors looking for a high quality pharmaceutical stock, Bristol Meyers is a good one. Many feel that the recent price drop is a good buying opportunity.4@ 2015. All Rights Reserved By Jason W Galanis.Get in touch with us!Name: Jason Galanis - Holmby Capital Group
Address: 1920 Bel Air Road, Los Angeles, Califonia, 90077
Email: [email protected]
Email: [email protected]
Contact No: 310-425-9575 5
